Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNC-T Therapy SV-102 in mCRPC
NCT06533644Phase 2Recruiting
- Sponsor
- Syncromune
- Start
- May 2025
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies, Device-based Delivery, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SYNC-T in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Syncromune. Started May 2025; status: recruiting.
02
Drugs
SYNC-T
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06533644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06533644.